Johanna C. Bendell, MD

Articles

Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRC

January 4th 2018

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Dr. Bendell Discusses Pembrolizumab in CRC

December 19th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

November 28th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

Dr. Bendell on the Future of Regorafenib for Patients With CRC

November 15th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer

April 27th 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Dr. Bendell on Remaining Questions With Regorafenib in HCC

April 22nd 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the remaining questions researchers have with regorafenib (Stivarga) for patients with hepatocellular carcinoma (HCC).

Dr. Bendell on Exciting Advancements in the Field of HCC

March 16th 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses exciting research and advancements in the field of hepatocellular carcinoma.

x